Zepbound phase 3 trials
Oral semaglutide 25 mg (Wegovy pill) , FDA-approved December 22, 2025, is the first oral GLP-1 approved for chronic weight management
@ro prepares for its Super Bowl debut starring Serena Williams
This review is also significant because it positions GHK-Cu in the context of gene data from the Broad Institute's Connectivity Map the same database used by pharmaceutical researchers to discover new drug applications
The Weight Watchers difference: At 6 months, our Med+ members on the GLP-1 Success Program lost 27 lbs, on average.^ ^Based on a 6-month clinical trial (n=180) of individuals who were enrolled between FebruaryApril 2024, with overweight or obesity taking semaglutide or tirzepatide for weight loss and related outcomes through the WW Clinic Program and participating in the GLP-1 companion nutrition program
Those two receptor pathways GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) are both involved in regulating appetite, blood sugar, and how the body processes food
